Background: Dysregulation of cell proliferation, usually controlled by cyclin-dependent kinases (CDKs), is a hallmark of cancers. Results: Ubiquitin C-terminal hydrolase L1 (UCH-L1) potentiates CDK activities to enhance cell proliferation. Conclusion: Potentiating CDK activities are a newly identified function of UCH-L1, and are involved in cancer growth. Significance: These findings should lead to a better understanding of, and novel therapies against, cancers.
CDK6. CDK4/6 are activated by D-type cyclins and function during the early to middle G1 phase. CDK2/cyclin E and CDK2/cyclin B complexes function in the late G1 phase and S phase, respectively. CDK1/cyclin B and CDK1/cyclinA complexes promote G2/M transition (1) . In contrast to these cell cycle-associated CDKs, CDK5 is not a part of the core cell-cycle machinery. CDK5 is activated by the neuron-specific p35 regulatory subunit and therefore functions in post-mitotic neurons (2, 3) .
It is well established that dysregulation of cell cycle/proliferation is one of the hallmarks of cancer cells (4) . Dysregulation of the cell cycle or CDK5 is also associated with neurodegenerative diseases (5, 6) . Therefore, elucidating the mechanisms underlying dysregulation of the cell cycle machinery in disease states is of critical importance.
Ubiquitin C-terminal hydrolase L1 (UCH-L1/PGP9.5) is normally expressed in restricted types of cells or organs, such as neurons, testes and ovaries (7) (8) (9) . The expression of UCH-L1 has also been observed in various human cancers: non-small-cell lung cancer; pancreatic cancer; invasive colorectal cancer; esophageal squamous cell carcinoma; myeloma; invasive breast cancer; parathyroid carcinoma; glioma cell lines; acute lymphoblastic leukemia cell line; chronic lymphocytic leukemia cell line; and Burkitt's lymphoma cell lines (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . This suggests that UCH-L1 is involved in cancer progression. Indeed, a recent study showed that UCH-L1-transgenic mice are prone to malignancy, primarily lymphomas and lung tumors (20) .
The I93M mutation in UCH-L1 has been observed in a family with dominant inherited Parkinson's disease (21) . We have shown that UCH-L1 I93M -transgenic mice exhibit partial loss of dopaminergic neurons (22) , indicating that the I93M mutation participates in the cause of familial Parkinson's disease. The E7A mutation in UCH-L1 has been recently reported as a causative mutation in a family with early-onset progressive neurodegeneration (23) .
UCH-L1 has been reported to cleave small adducts, such as amino acids, from the C-terminus of ubiquitin in a cell-free system. However, it is not able to hydrolase the K48 isopeptide bond in vitro (24) . Under in vitro conditions, UCH-L1 can also cleave ubiquitin gene products, -linked ubiquitin oligomers (ubiquitin B, ubiquitin C) or -linked ubiquitin fused to ribosomal protein S27a (ubiquitin A), albeit very slowly (24) . UCH-L1 was also reported to act as a ubiquitin ligase in a cell-free system (25) . Other than these enzymatic activities, we have shown that UCH-L1 stabilizes monoubiquitin through interaction with monoubiquitin (26) . However, the molecular functions of UCH-L1 involving cancer progression or cell-cycle control remain largely unknown.
In addition to monoubiquitin, we have shown that UCH-L1 physically interacts with multiple proteins, including / -tubulin, LAMP-2A, Hsc70 and Hsp90 (27) (28) (29) . The levels of interactions of these proteins with UCH-L1 C90S , which lacks hydrolase activity but maintains binding affinity for monoubiquitin, were not altered compared with that of UCH-L1
WT (27, 28) . From these observations, we hypothesized that UCH-L1 can function independently of a ubiquitin system. Another deubiquitinating enzyme, UBP43/USP18, is known to negatively regulate interferon signaling independent of its isopeptidase activity (30) . In this study, we further screened for UCH-L1-interacting proteins to clarify the molecular functions of UCH-L1.
His-tag at the C-terminus and an S-tag at the N-terminus were constructed by ligating the cDNAs encoding CDK4 into the pET-29b(+) vector (Novagen). The pCI-neo-CDK5 plasmid containing human D144N CDK5 was generated using a QuikChange Site-Directed Mutagenesis Kit.
Cell culture and transfection
Neuro2a, COS-7 and HeLa cells were cultured as described previously (31, 32) . H727 and MCF cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. NIH-3T3 cells stably expressing human UCH-L1 with a FLAG-HA double tag at the N-terminus were cultured as described previously (27) . Transient transfection of COS-7 cells with each vector was performed using the FuGENE 6 Transfection Reagent (Roche) as described previously (33) . HeLa cells were transfected with plasmids using Lipofectamine LTX (Invitrogen) as described previously (34) .
Antibody array
An antibody array assay was performed using an AntibodyArray (Hypromatrix) according to the manufacturer's protocols. Briefly, lysate was prepared from NIH-3T3 cells stably expressing human UCH-L1 with a FLAG-HA double tag. The array containing 400 antibodies was incubated with lysate, and binding UCH-L1 was detected using an anti-HA antibody conjugated to horseradish peroxidase (Sigma).
Immunoblotting SDS-PAGE was performed under reducing conditions, and immunoblotting was performed according to standard procedures as described previously (35, 36) . Anti-CDK4, -CDK5, -CDK6, -Histone H1, -p35 and -cyclin D1 antibodies were purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-CDK1, -Rb and -phospho-Rb (Ser-795) antibodies were from Cell Signaling. Anti-CDK2 and -p27 antibodies were purchased from BD Biosciences. Anti-UCH-L1, -phospho-Histone H1, -phospho-p27 (Ser-10) and --actin were from UltraClone, Upstate, Zymed, Invitrogen and Sigma, respectively. An anti-DYKDDDDK (FLAG) antibody was from Wako.
Immunoprecipitation
Immunoprecipitation was performed as previously described (27) .
Preparation of recombinant proteins and pull-down assay
Recombinant glutathione S-transferase (GST) and GST-tagged UCH-L1 were prepared as described previously (27) . Recombinant CDK4 with a His-tag at the C-terminus and an S-tag at the N-terminus was prepared as described previously (32) .
A pull-down assay was performed according to the methods described previously (37, 38) . Glutathione-Sepharose beads (GE Healthcare) were blocked with 3% BSA for 15 h in order to prevent non-specific binding of proteins to the beads, and washed three times with PBS containing 0.05% Triton X-100. Twenty microliters of glutathione beads blocked with BSA, 150 pmol of recombinant CDK4, and 100 pmol of recombinant GST-UCH-L1 or GST were mixed and incubated for 2 h in PBS containing 0.05% Triton X-100. After beads were washed three times with PBS containing 0.05% Triton X-100, proteins were eluted with SDS sample buffer.
Assessment of cell proliferation
One day before transfection, cells were seeded at 1 10 4 , 2 10 4 (HeLa and Neuro2a) or 4 10 4 cells (H727 and MCF7) per well in 24-well plates. After transfection with plasmids or siRNA, cells were incubated for the indicated time periods. Viable and dead cell numbers were counted using a Vi-CELL XR cell viability analyzer (Beckman coulter). The relative number of viable cells was measured using a CellTiter-Glo Luminescent Cell Viability Assay (Promega). In some experiments, CDK4 inhibitor (219476, Merck Millipore) was added to cells.
The BrdU incorporation assay was performed using a Cell Proliferation ELISA BrdU kit (Roche). Briefly, HeLa cells transfected with UCH-L1 or an empty vector were incubated with BrdU for 3 h then fixed. Cells were then immunostained with anti-UCH-L1 and anti-BrdU antibodies. After BrdU-positive cells were counted, the percentage of BrdU-positive cells among total cells transfected with empty vector or UCH-L1 was calculated.
In vitro kinase assay
In vitro kinase assays of CDKs were performed according to the procedure of Kawauchi et al. (39) . Purified CDK1-cyclin B1, CDK4-cyclin D1, CDK5-p35, Histone H1, Rb, p27 and UCH-L1 were purchased from Upstate, Biaffin GmbH, Upstate, New England BioLabs, QED Bioscience, Santa Cruz and Boston Biochem, respectively. Purified proteins were incubated in 50 μl of kinase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 200 μM ATP, 1 μM DTT, 0.1% BSA) at 30°C for the indicated time, and analyzed by immunoblotting.
CDK4 activity in cultured cells were measured according to the method described by Smith et al. (40) . Briefly, CDK4 was immunoprecipitated from the cell lysate using anti-CDK4 antibody (Santa Cruz) and Protein G Sepharose beads (GE Healthcare). Beads were then mixed with purified Rb in kinase buffer and incubated at 30°C for 30 min. Phosphorylation levels of Rb were analyzed by immunoblotting.
siRNA preparation and transfection Double-stranded siRNAs targeting UCH-L1, EGFP and CDK4 were purchased from RNAi Co., Ltd. (Tokyo, Japan). Sequences targeted by siRNA were selected using siDirect (RNAi Co., Ltd) and were: mouse UCH-L1 siRNA-A (sense, 5 -GUU AGC CCU AAA GUU UAC UUC-3 and antisense, 5 -AGU AAA CUU UAG GGC UAA CUU-3 ); mouse UCH-L1 siRNA-B (sense, 5 -CUG AAG CCG AUG GAG AUU AAC-3 and antisense, 5 -UAA UCU CCA UCG GCU UCA GCU-3 ); EGFP siRNA for mouse cells (sense, 5 -GCC ACA ACG UCU AUA UCA UGG-3 and antisense, 5 -AUG AUA UAG ACG UUG UGG CUG-3 ); human UCH-L1 siRNA-A (sense, 5 -GAC AAG AAG UUA GUC CUA AAG-3 and antisense, 5 -UUA GGA CUA ACU UCU UGU CCC-3 ); human UCH-L1 siRNA-B (sense, 5 -GCA CAA UCG GAC UUA UUC ACG-3 and antisense, 5 -UGA AUA AGU CCG AUU GUG CCA-3 ); EGFP siRNA for human cells (sense, 5 -CAG CAC GAC UUC UUC AAG UCC-3 and antisense, 5 -ACU UGA AGA AGU CGU GCU GCU-3 ); and human CDK4 siRNA (sense, 5 -GUG CCA CAU CCC GAA CUG ACC-3 and antisense, 5 -UCA GUU CGG GAU GUG GCA CAG-3 ). EGFP siRNAs were used as a control. Neuro2a cells were transfected with siRNA using X-treamGENE (Roche). H727 and MCF7 cells were transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen).
Xenograft cancer models
Male, 5-week-old BALB/c nu/nu mice were purchased from CLEA Japan (Tokyo, Japan). These athymic nude mice were anesthetized by intraperitoneal injection of Somnopentyl (50 mg/kg), and inoculated with 3 10 7 MCF7 cells containing 50% Matrigel (BD Bioscience, CA) into the left flank of nude mice on day 0. After confirmation of tumor growth at 50 mm 3 or more, the siRNAs was intratumorally injected into mice on days 14, 21 and 28. To achieve effective delivery, the siRNAs were mixed with atelocollagen (AteloGene Local Use; Koken, Tokyo, Japan). The siRNA/atelocollagen complexes were prepared according to the manufacturer's guidelines (1.0 mg/kg body weight; approximately 20 μg/200 μL/injection). Tumor size was measured from above the skin, and tumor volume was estimated by measuring in two directions and calculated by the following formula: tumor volume (mm 3 ) = (length) (width) 2 0.5. Forty days after inoculation of the cells, tumors were dissected and weighed. All animal experiments were approved by the animal experimentation committee of the National Center of Neurology and Psychiatry.
Statistical analysis
For comparisons between two groups, statistical difference was determined by Student's t test. For comparison of more than two groups, Dunnett's multiple comparison test or Fisher's PLSD test was used. * and ** indicate P < 0.05 and P < 0.01, respectively.
Results

UCH-L1 interacts with CDK1, CDK4, CDK5 and CDK6.
To clarify the molecular functions of UCH-L1, we screened for UCH-L1-interacting proteins using an array containing 400 antibodies (Table S1 ). The array was incubated with cell lysate containing HA-tagged UCH-L1, and binding UCH-L1 was detected using an anti-HA antibody ( Figure 1A ). Signal intensities of the spots with antibodies against CDK1, CDK2, CDK4 and CDK6 were higher than that of the average intensity of 400 spots, suggesting interactions of CDK family proteins with UCH-L1 ( Figure 1A , B). To confirm the interactions between UCH-L1 and CDKs, co-immunoprecipitation assays were performed using COS-7 cells transiently expressed with FLAG-tagged UCH-L1. Endogenous CDK1, CDK4, CDK5 and CDK6 were co-precipitated with FLAG-tagged UCH-L1, while endogenous CDK2 was not ( Figure 1C, D) . We also detected the interaction of endogenous UCH-L1 with endogenous CDK1 or CDK4 using Neuro2a cells, which endogenously express UCH-L1 ( Figure 1E ).
We found that the levels of CDK1, CDK4, CDK5 interacting with UCH-L1 I93M are higher than the amount interacting with UCH-L1 WT (2.3-, 3.1-and 2.7-fold increases, respectively) ( Figure 1C ). The interactions of CDK with UCH-L1 C90S were not notably changed compared with those of UCH-L1 WT ( Figure 1C ). UCH-L1
C90S
, in which the active center cysteine residue is substituted with serine, exhibits no hydrolase activity and presumably possesses no ligase activity (25, 41) . The hydrolase and ligase activities of UCH-L1
I93M are reduced compared with those of UCH-L1
WT (25, 41 (26, 27) . Thus, the levels of interactions between UCH-L1 and CDKs are independent of the known ubiquitin-related functions of UCH-L1.
In contrast to endogenous CDK2, overexpressed CDK2 interacted with FLAG-tagged UCH-L1 ( Figure S1 ). We hypothesized that the endogenous interaction between UCH-L1 and CDK2 is below the limit of detection. Given that endogenous CDK2 did not interact with UCH-L1, we did not conduct any further analyses on CDK2.
UCH-L1 enhances the kinase activity of CDK
We next tested whether UCH-L1 affects the kinase activities of CDKs. To examine direct effects of UCH-L1 on kinase activities of CDKs, we first utilized a cell-free kinase assay. We used Histone H1 as an in vitro substrate of CDK1-Cyclin B, Rb for CDK4-Cyclin D, and p27 for CDK5-p35 (39) . Intriguingly, a kinase assay in which purified CDK1-Cyclin B, Histone H1 and UCH-L1 were mixed in vitro revealed that UCH-L1 enhances the phosphorylation of Histone H1 by CDK1-Cyclin B (1.6-fold increase at 30 min) (Fig. 2A) . Similarly, UCH-L1 enhanced the phosphorylation of Rb and p27 by CDK4-Cyclin D and CDK5-P35, respectively in a cell-free kinase assay (1.8-and 1.8-fold increases at 30 min, respectively) (Fig. 2B, C) . These results indicate that UCH-L1 enhances the kinase activity of CDK1, CDK4, and CDK5.
We also assessed the effects of UCH-L1 on the kinase activity of CDK4 and CDK5 using a cell-based kinase assay (39) . UCH-L1, CDK4, cyclin D and Rb were co-expressed in COS-7 cells, and the phosphorylation levels of Rb were measured using immunoblotting. Consistent with the in vitro assay, UCH-L1 increased the phosphorylation levels of Rb ( Figure 2D, F) . In assays expressing UCH-L1, CDK5, p35 and p27, UCH-L1 was observed to also enhance the phosphorylation levels of p27 ( Figure 2E, G) . In the absence of overexpressed cyclin D ( Figure 2D , lane 7-9) and p35 ( Figure 2E , lane 4-6), UCH-L1 had no effect on the phosphorylation of Rb and p27 respectively, indicating that UCH-L1 increased the phosphorylation levels of Rb and p27 through CDK4-cyclin D or CDK5-p35. As a negative control for overexpression of UCH-L1, we also examined the effects of other proteins interacting with CDKs on kinase activity. We found that neurodegenerative disease-linked mutant SOD1 also interacts with CDK4, but mutant SOD1 did not enhance CDK4 activity ( Figure S2A, B) .
To investigate the mechanism of how UCH-L1 enhances the kinase activity of CDK-Cyclin, we used UCH-L1 I93M and UCH-L1 C90S in cell-based kinase assays.
Compared with UCH-L1
WT , UCH-L1 I93M further elevated the phosphorylation of Rb (lanes 2 and 3 in Figures 2D and 2F ) and p27 (lanes 2 and 3 in Figures 2E and 2G ). UCH-L1
C90S enhanced the phosphorylation of Rb at similar levels to UCH-L1 WT ( Figure 2H and I). Taken together with the results showing that UCH-L1
I93M displays increased levels of interaction with CDKs ( Figure  1C ), these results indicate that the enhancement of CDKs activities by UCH-L1 is independent of the known ubiquitin-related functions of UCH-L1, but correlates with the interaction levels between UCH-L1 and CDKs.
Because CDKs are activated by interacting with cyclin regulatory subunits, we examined whether UCH-L1 augments the interaction between CDKs and cyclins. Co-immunoprecipitation assays showed that UCH-L1 does not affect interaction levels between CDK4 and cyclin D, CDK5 and p35, and CDK1 and Cyclin B (Figure S3A-C) . We also tested whether UCH-L1 competes with the CDK inhibitors p27 (Kip1) or p21 (Cip1) for binding to CDKs. UCH-L1 did not affect the level of interaction between CDK1 and p21, CDK1 and p27, CDK4 and p21, and CDK4 and p27 ( Figure  S3D , E), indicating that UCH-L1 does not compete with p27 or p21 for the binding to CDKs. Our results support the idea that UCH-L1 directly enhances the kinase activity of CDKs.
Interaction regions between UCH-L1 and CDK4
We next assessed the interaction regions between UCH-L1 and CDKs to investigate the mechanism(s) of interaction of UCH-L1 with CDKs. Because CDKs share high sequence homology (CDK4 shares 73, 74 and 90% sequence homology with CDK1, CDK5, CDK6, respectively) ( Figure S4 ), and UCH-L1 had similar effects on the enhancement of kinase activity of CDK1, CDK4 and CDK5 (Figure 2 ), we focused on CDK4 and mainly used CDK4 in our experiments.
We investigated whether UCH-L1 directly interacts with CDK4 using a pull-down assay. Recombinant CDK4 was pulled down with recombinant UCH-L1 ( Figure 3A ). This result indicates that UCH-L1 directly interacts with CDK4. To determine the region of UCH-L1 that interacts with CDK4, we performed co-immunoprecipitation assays using deletion mutants of UCH-L1 incorporating FLAG tags ( Figure 3B ). CDK4 was found to interact with amino acid (aa) residues 60-223 or 100-223 in UCH-L1, but not with aa 1-150 ( Figure 3C ), indicating that CDK4 interacted with a region within aa 151-223 of UCH-L1. We generated several deletion mutants of UCH-L1 with GFP and FLAG tags ( Figure 3D) , and carried out co-immunoprecipitation assays. CDK4 interacted with aa 148-190, 160-190, 148-223 and 160-223, but not with aa 188-223 of UCH-L1 ( Figure 3E ). These results indicate that CDK4 mainly interacts with aa 160-190 of UCH-L1. The aa 160-190 are distinct from Asp-30, which is required for monoubiquitin binding ( Figure 3F ). This is consistent with results showing that UCH-L1 CDK-potentiation activity is independent of the known ubiquitin-related functions of UCH-L1.
Co-immunoprecipitation assays using a series of alanine substitutions of UCH-L1 (39 mutants) revealed that R63A, E174A, D176A and H185A mutations notably increase interactions with CDK4 ( Figure S5A ). Glu-174, Asp-176 and His-185 are within aa 148-190, with Arg-63 located adjacent to this region ( Figure S5B ), supporting the notion that CDK4 interacts with aa 160-190 of UCH-L1.
To determine the region of CDK4 that interacts with UCH-L1, we performed co-immunoprecipitation assays using several deletion mutants of CDK4 ( Figure 4A ). UCH-L1 interacted with aa 151-218 of CDK4, but not with aa 2-80 and 219-294 of CDK4 ( Figure 4B ). UCH-L1 interacted only slightly with aa 81-150 ( Figure 4B ). The interacting region, aa 151-218, of CDK4 contains a T-loop ( Figure 4A ), which conformationally regulates CDKs kinase activity (42) , suggesting that UCH-L1 may affect the conformation of CDKs in enhancing kinase activity. This region of CDK4 shares a particularly high homology: 82, 84 and 97% sequence homology with the corresponding regions of CDK1, CDK5, and CDK6, respectively ( Figure  S4 ).
Overexpression of UCH-L1 enhances cell proliferation
Given that UCH-L1 augments the kinase activity of CDK1 and CDK4, we hypothesized that UCH-L1 enhances cell proliferation. We assessed the effects of UCH-L1 overexpression on the proliferation of HeLa cells that do not express detectable levels of UCH-L1 (43) . Compared with transfection of the empty vector, overexpression of UCH-L1 significantly increased viable cell numbers without affecting cell death ( Figure 5A ), indicating that overexpression of UCH-L1 enhances proliferation in these cells. When relative viable cell numbers were measured by ATP-based cell viability assays, overexpression of UCH-L1 in HeLa cells also increased the viable cell numbers compared with control transfections ( Figure 5B ). Therefore, we used this assay for the measurement of viable cell numbers in several experiments. We examined the effect of UCH-L1 on the proliferation of COS-7 cells, which also do not express detectable levels of UCH-L1 (25) . In these cells, overexpression of UCH-L1 enhanced cell proliferation ( Figure S6A,  B) .
For further confirmation of the effect of UCH-L1 on cell proliferation, we examined proliferation over time, and BrdU incorporation in HeLa cells. In the time course proliferation assay, UCH-L1 enhanced proliferation of HeLa cells (P<0.01, two-way ANOVA) ( Figure 5C ). Consistent with the enhancement of proliferation, overexpression of UCH-L1 increased the incorporation of BrdU ( Figure 5D ).
To investigate whether enhancement of the kinase activity of CDKs is involved in the enhancement of cell proliferation by UCH-L1, we used UCH-L1 I93M and UCH-L1 C90S in proliferation assays; both enhanced proliferation ( Figure 5E (Figure 2 ), enhancement of proliferation by UCH-L1 is independent of the known ubiquitin-related functions of UCH-L1, and correlates with the levels of enhancement of CDK4 by UCH-L1. These results suggest that enhancement of cell proliferation by UCH-L1 is mediated by CDKs. We investigated this further by observing the effects of UCH-L1 overexpression on the proliferation of cells treated with CDK4 inhibitors, and in cells where CDK4 expression was knocked down ( Figure S7 ). We observed that UCH-L1 did not significantly affect proliferation ( Figure S7) .
To exclude the possibility that UCH-L1 enhances cell proliferation through humoral factors, we tested the effect of conditioned media from UCH-L1-overexpressed cells on proliferation. Treatment of cells with conditioned medium from cells overexpressing UCH-L1 had no effect on proliferation compared with the control conditioned medium ( Figure 5F ). This indicates that enhancement of cell proliferation by UCH-L1 is not mediated by alternating humoral factors, such as increasing growth factors and decreasing growth-inhibition factors.
Ectopic expression of CDK5 attenuates the interaction between UCH-L1 and CDK4, and inhibits the enhancement of proliferation by UCH-L1
Because of high sequence homology among the CDKs, we assumed that ectopic expression of CDK5 may result in the inhibition of interactions of UCH-L1 with cell cycle-associated CDKs. It may also inhibit the enhancement of proliferation by UCH-L1. We observed that overexpression of CDK5 attenuated the interaction between overexpressed CDK4 and UCH-L1 (1.5-fold decrease) ( Figure 5G , lane 2 and 4). In HeLa cells overexpressing CDK5, overexpression of UCH-L1 did not enhance cell proliferation ( Figure 5H ). To exclude the possibility of detrimental effects from the overexpression of CDK5, we used a kinase dead CDK5 (D144N) (44) . We confirmed that CDK5 D144N interacted with UCH-L1 at a level comparable to that with CDK5 WT ( Figure S8 ). In cells overexpressing CDK5 D144N , overexpression of UCH-L1 did not enhance proliferation ( Figure 5I ). These results strongly suggest that UCH-L1 enhances cell proliferation through interaction with cell cycle-associated CDKs.
Knockdown of UCH-L1 reduces cell proliferation
To assess the role of endogenous UCH-L1 on CDK activity and cell proliferation, we examined the loss of functional effects of UCH-L1 using siRNA in the mouse neuroblastoma cell line, Neuro2a, which endogenously expresses UCH-L1. We used two different siRNA sequences for knockdown of mouse UCH-L1. Both siRNA decreased protein levels of UCH-L1 to approximately 25% ( Figure  6A ). Knockdown of UCH-L1 by each siRNA significantly decreased the levels of cell proliferation in Neuro2a cells without increasing cell death ( Figure 6B) . As a control, we tested the effects of transfecting UCH-L1 siRNAs on proliferation of HeLa cells, as these do not express detectable levels of UCH-L1. Proliferation rates were not reduced in these HeLa cells ( Figure S9) . We tested the effect of UCH-L1 knockdown on the kinase activity of CDK4. CDK4 was immunoprecipitated from Neuro2a cells in which UCH-L1 was knocked down, and subjected to in vitro kinase assays. Knockdown of UCH-L1 by each siRNA reduced kinase activity ( Figure 6C,  D) . We confirmed that the total levels of cyclin D were unaltered in cells where UCH-L1 expression was knocked down ( Figure 6A ). These results indicate that reduced CDK4 activity in vitro is not a consequence of reduced proliferation, and that endogenous UCH-L1 also enhances the kinase activity of CDK4 and cell proliferation.
We also examined the role of endogenous UCH-L1 on the proliferation of human cancer cells that endogenously express UCH-L1. We prepared two different siRNA sequences for knockdown of human UCH-L1. In a human lung carcinoid cell line, H727, hUCH-L1 siRNA-A and -B decreased protein levels of UCH-L1 to 46% and 58%, respectively ( Figure  6E ). Knockdown of UCH-L1 by each siRNA reduced the viable cell number without increasing cell death, indicating that knockdown of UCH-L1 reduces the proliferation of H727 cells ( Figure 6F ). Because both inhibitory effects on proliferation and knockdown efficiency of siRNA-B were high compared with those of siRNA-A, we used siRNA-B for the following experiments. In the human breast adenocarcinoma cell line, MCF7, knockdown of UCH-L1 also reduced viable cell numbers without increasing cell death, indicating that knockdown of UCH-L1 reduces proliferation of MCF7 cells ( Figure 6G, H) . We confirmed that siRNA-B did not reduce proliferation levels of HeLa cells ( Figure S9 ). Thus, endogenous UCH-L1 enhances proliferation of certain types of human cancer cells.
Local administration of UCH-L1 siRNA into a subcutaneous xenograft tumor reduced tumor growth.
To examine whether endogenous UCH-L1 also enhances proliferation of tumor cells in vivo, we performed subcutaneous xenograft studies. MCF7 cells (3 10 7 ) were inoculated into nude mice. After confirmation of tumor formation, siRNAs were delivered into tumors once a week over 3 weeks ( Figure 7A) . Measurement of the width of tumors and estimation of tumor volume over time showed that administration of UCH-L1 siRNA significantly reduced tumor growth compared with that of control siRNA (P<0.05, two-way ANOVA) ( Figure 7B, C) . Measurement of the wet weight of tumors also demonstrated that administration of UCH-L1 siRNA significantly reduced tumor growth ( Figure 7D, E) .
To exclude the possibility that UCH-L1 siRNA reduced tumor growth via alterations in the immune system, splenocytes were isolated from siRNA-treated nude mice, and T cell-mediated cytotoxicity measured. We observed that UCH-L1 siRNA did not affect T cell-mediated toxicity ( Figure S10 ). UCH-L1 siRNA did not affect body weight, numbers of red blood cells and white cells, in mice with xenograft tumors compared with control siRNA ( Figure S10 ).
Discussion
Enhancement of CDK activity by UCH-L1
In this study, we have shown that UCH-L1 physically interacts with CDK1, CDK4 and CDK5 and enhances CDKs activity. Activation of CDKs requires cyclin binding and phosphorylation of a conserved threonine residue by the CDK-activating kinase (45) . In contrast, phosphorylation of a conserved threonine-tyrosine pair in CDKs or binding of CDK inhibitors is known to block kinase activity (45) . UCH-L1 enhances kinase activity of CDKs in a cell-free system containing only buffer and purified proteins (Figure 2A-C) . UCH-L1 did not compete with the CDK inhibitors p27 (Kip1) or p21 (Cip1) for binding to CDKs ( Figure S3 ). UCH-L1 is not a kinase nor a phosphatase, indicating that UCH-L1 enhances kinase activity independently of phosphorylation of CDKs and CDK inhibitors. In the cell-based kinase assay, UCH-L1 enhanced CDK activity only in the presence of overexpressed cyclin or p35 ( Figure 2D, E) . UCH-L1 does not modify the interaction levels between CDKs and cyclin ( Figure S3 ). Thus, UCH-L1 does not activate CDKs, but potentiates CDKs/cyclins activity. To our knowledge, this is the first report of a potentiator of CDKs/cyclins.
Using UCH-L1 mutants, we have shown that the enhancement of CDKs activities by UCH-L1 is independent of the known ubiquitin-related functions of UCH-L1, but correlates with interaction levels between UCH-L1 and CDKs. Compared with UCH-L1
WT , UCH-L1 I93M further enhanced CDK4 activity and interacted with CDKs at higher levels ( Figure 1C, 
2D-G); UCH-L1
C90S interacted with CDKs and enhanced CDK4 activity at levels comparable to UCH-L1 WT ( Figure 1C, 2H, I ). Similarly, another deubiquitinating enzyme, UBP43/USP18, is known to negatively regulate interferon signaling independent of its isopeptidase activity (30) .
The precise mechanism(s) of how UCH-L1 enhances CDKs activities is currently unknown. Because UCH-L1 interacts with a region of CDK4 containing a T-loop ( Figure 4A,  B) , which conformationally regulates kinase activity of CDKs (42), UCH-L1 possibly affects the conformation of CDKs in enhancing kinase activity; however, further structural studies are needed to elucidate this point.
Enhancement of proliferation by UCH-L1
We have shown that overexpression of UCH-L1 enhances proliferation of two cell lines, HeLa and COS-7, both of which do not express UCH-L1 ( Figure 5, S6) . Knockdown of UCH-L1 reduced proliferation in three cell lines, Neuro-2a, H727 and MCF7, all of which endogenously express UCH-L1 ( Figure 6 ). These results indicate that UCH-L1 enhances proliferation in certain types of cells. UCH-L1 is expressed in restricted types of cells or organs, including neurons, testes and ovaries. Previous studies have shown that UCH-L1 is expressed in spermatogonial cells, and the levels of proliferation of spermatogonial cells in UCH-L1 deficient mice (gad mice) are decreased compared with that in wild-type mice (8, 46) . This indicates that UCH-L1 is required for the normal proliferation of these cells in vivo, and our results are consistent with these findings.
The following observations indicate that enhancement of proliferation by UCH-L1 is at least partly mediated by enhancement of CDK1 and CDK4 activities by UCH-L1 ( Figure S11 ). First, UCH-L1 enhances CDK1 and CDK4 activities (Figure 2 ), which are known to be essential for proliferation and to enhance proliferation, respectively. CDK1 is the only essential CDK for the mammalian cell cycle (47) . CDK4-deficient mice are small, and mouse embryonic fibroblasts derived from these mice exhibit a delayed S phase re-entry (48) . Second, in cells overexpressing CDK5, which attenuates the interaction of UCH-L1 with CDK4 and presumably with CDK1, overexpression of UCH-L1 did not alter proliferation ( Figure 5H ).
Third, enhancement of proliferation by UCH-L1 is independent of the known ubiquitin-related functions of UCH-L1, but correlates with the interaction levels between UCH-L1 and CDKs, and with the enhanced levels of CDK4 by UCH-L1 ( Figure 1C, 2D-I, 5E ). Fourth, in cells treated with CDK4 inhibitors, or where CDK4 expression was knocked down, UCH-L1 did not enhance proliferation ( Figure S7) . Fifth, the enhancement of cell proliferation by UCH-L1 is not mediated by alterations in humoral factors ( Figure 5F ).
However, this does not necessarily rule out the possibility that enhancement of proliferation via UCH-L1 is partially mediated by other mechanisms. Other than CDKs, UCH-L1 has been reported to interact with JAB1, a protein involved in cell proliferation (49) .
Roles of UCH-L1 in human diseases
Dysregulation of the cell cycle and proliferation is a hallmark of cancer cells. Although UCH-L1 is expressed in restricted types of cells or organs, UCH-L1 has been reported to be expressed in various human cancers. In vitro and in vivo studies have shown that UCH-L1 enhances the invasive potential of tumor cells (50) . Another study showed that UCH-L1 transgenic mice are prone to malignancy, primarily lymphomas and lung tumors (20) . UCH-L1 enhances proliferation in pre-malignant tissues of UCH-L1-c-myc-double transgenic mice (20) . Thus, in certain types of tumors, UCH-L1 functions as an oncogenic protein rather than a tumor suppresser. Consistent with this notion, we have shown that endogenous UCH-L1 enhances proliferation of tumor cells both in vitro and in vivo. This is the first to show that endogenous UCH-L1 in cancer cells enhances proliferation in vivo.
In contrast to the expression of UCH-L1 in various cancers, the UCHL1 gene is silenced in human colorectal, ovarian cancers and renal cell carcinoma via promoter methylation (51, 52) . Transfection of UCH-L1 in renal cancer cell lines resulted in growth inhibition, suggesting that UCHL1 functions as a tumor suppressor gene in these cells (52) . Taken together, these observations indicate that UCH-L1 possesses a dual role, as an oncogenic protein and a tumor suppressor. The molecular mechanisms to describe how UCH-L1 functions in opposite ways are currently unknown and require further investigation.
Dysregulation of the cell cycle is also associated with neurodegenerative diseases. A number of laboratories have reported a correlation between neuronal loss and the appearance of cell cycle-related proteins, including CDK4, in the brains of Alzheimer's disease patients (5, (53) (54) (55) (56) (57) . Mitosis-associated proteins have also been reported to be aberrantly expressed in dopaminergic neurons in patients with Parkinson's disease (6) . In a mouse model of Parkinson's disease, CDK5 has been shown to be a mediator of dopaminergic neuronal loss (40) . We found that UCH-L1 I93M further elevates the kinase activity of CDK4 and CDK5 compared with UCH-L1 WT ( Figure 2D-G) . Whether enhancement of CDKs activities by UCH-L1 is involved in the pathogenesis of neurodegenerative diseases remains an interesting issue to be resolved. We believe our findings in this study will significantly contribute to our understanding of cell cycle-associated diseases.
The abbreviations used are: Cyclin-dependent kinases (CDKs), Ubiquitin C-terminal hydrolase L1 (UCH-L1), glutathione S-transferase (GST). by guest on November 18, 2017 
